You are currently viewing a new version of our website. To view the old version click .

The Post-Marketing Life of Vaccines

This special issue belongs to the section “Vaccines and Public Health“.

Special Issue Information

Dear Colleagues,

The recent experience of the SARS-COV-2 pandemic and the universal mass vaccination carried out to fight against this emergency is an important lesson for vaccinologists.

Vaccines against SARS-COV-2 were prepared in 8 months, and a large amount of the information for the safety, long-term immunogenicity, and effectiveness of these vaccines was from post-marketing studies.

This indicates that research on vaccines should not and cannot stop after marketing authorization, as an important portion of evidence actually comes from post-marketing and phase IV studies.

We welcome contributions including original research articles as well as field reviews relating to this research topic.

Prof. Dr. Silvio Tafuri
Dr. Pasquale Stefanizzi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • effectiveness of vaccination programs
  • safety of vaccines
  • long-term immunogenicity
  • phase IV studies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Published Papers

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Vaccines - ISSN 2076-393X